(Source: Neovacs SA) PRESS RELEASE PRESS RELEASE PRESS RELEASE NEOVACS LAUNCHES €6.3 MILLION CAPITAL INCREASE TO FINANCE CLINICAL PROOF-OF-CONCEPT FOR THE TNF-KINOID Capital increase with preemptive subscription rights ("Rights") for existing shareholders Subscription ratio of 2 new shares for 9 existing shares Subscription price: € 1.80 Amount targeted € 6.265 M, with an option to increase to € 7.205 M Subscription period : February 19, 2013 to March 1, 2013 Eligible for TEPA/ISF tax provisions within the maximum allowed amount of €2.5M1 NEOVACS draws investors' attention to Section 4 "Risk factors" of the prospectus registered with the "Autorité des Marchés...
↧